FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032181493> ?p ?o ?g. }

• W3032181493 endingPage "e16685" @default.
• W3032181493 startingPage "e16685" @default.
• W3032181493 abstract "e16685 Background: Hepatocellular carcinoma (HCC) with microvascular invasion (MVI) is established with poorer outcome and more frequent postoperative recurrence. Sorafenib is the first target drug that successfully prolongs the survival of advanced HCC, but it failed to prolong the survival of HCC after radical resection or ablation in the STORM study. After that, series studies revealed that sorafenib could improve the survival of HCC with MVI after surgery, while most studies with positive results were retrospective ones. Methods: A multicenter, prospective non-randomized, open-label study was performed in pts undergoing radical resection, postoperative pathology confirming HCC with MVI (BCLC A or B stage; T2 or part T3aN0M0). Pts in the treatment group (S group) started sorafenib within 4-6 postoperative weeks at the dose of 400mg per day at most 2 years, and the control group (C group) never received sorafenib. The primary endpoint is recurrence-free survival (RFS) rate at the 2nd postoperative year, and the secondary endpoints include postoperative median time to recurrence (TTR), 1-year postoperative RFS, pts’ overall survival (OS), and safety. This study was approved by Ethical Committee of Sun Yat-sen University Cancer Center, and registered at ClinicalTrials.gov with number NCT02867280. Results: Between 1 June 2015 and 31 August 2019, 154 eligible pts from 3 academic hospitals in China were enrolled (83 in C group and 53 in S group). Baseline demographics were balanced between the two groups. The 2-yr RFS rate was 56.1% in the S group vs. 55.7% in the C group, respectively ( P = 0.955), and the median RFS was 15.5 vs. 16.0 months ( P = 0.827).The recurrence rates at the 1st postoperative year were 38.6% vs. 34.0% ( P = 0.568), and the median TTR was the same as the RFS. There were 31 pts (54.4%) of the S group experienced treatment-related adverse events (AEs). The most common AE was hand-foot syndrome (HFS, 19/57, 10 pts ≥ grade-2). Other AEs included diarrhoea (15/57, 26.4%), alopecia (11/57, 19.3%), hypertension (5/57, 8.8%) and decreased platelet (3/57, 5.3%), and gastric ulcer with bleeding (1/57, 1.8%). Sorafenib was interrupted or discontinued in 7 pts due to AEs. Recruiting of this study was closed according to the results of the planned mid-term analysis, and all pts were followed on schedule to observe the other survival data. Conclusions: Postoperative sorafenib treatment with dose of 400mg once daily was well tolerated, but did not improve the RFS and TTR of Chinese HCC pts with MVI. Clinical trial information: NCT02867280 ." @default.
• W3032181493 created "2020-06-05" @default.
• W3032181493 creator A5002647988 @default.
• W3032181493 creator A5020613063 @default.
• W3032181493 creator A5035282477 @default.
• W3032181493 creator A5038290557 @default.
• W3032181493 creator A5055611906 @default.
• W3032181493 creator A5076466079 @default.
• W3032181493 creator A5083801400 @default.
• W3032181493 date "2020-05-20" @default.
• W3032181493 modified "2023-09-24" @default.
• W3032181493 title "Sorafenib as an adjuvant therapy for hepatocellular carcinoma with microvascular invasion after radical resection: A prospective multicenter nonrandomized controlled study." @default.
• W3032181493 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e16685" @default.
• W3032181493 hasPublicationYear "2020" @default.
• W3032181493 type Work @default.
• W3032181493 sameAs 3032181493 @default.
• W3032181493 citedByCount "3" @default.
• W3032181493 countsByYear W30321814932021 @default.
• W3032181493 countsByYear W30321814932022 @default.
• W3032181493 crossrefType "journal-article" @default.
• W3032181493 hasAuthorship W3032181493A5002647988 @default.
• W3032181493 hasAuthorship W3032181493A5020613063 @default.
• W3032181493 hasAuthorship W3032181493A5035282477 @default.
• W3032181493 hasAuthorship W3032181493A5038290557 @default.
• W3032181493 hasAuthorship W3032181493A5055611906 @default.
• W3032181493 hasAuthorship W3032181493A5076466079 @default.
• W3032181493 hasAuthorship W3032181493A5083801400 @default.
• W3032181493 hasConcept C126322002 @default.
• W3032181493 hasConcept C141071460 @default.
• W3032181493 hasConcept C143998085 @default.
• W3032181493 hasConcept C203092338 @default.
• W3032181493 hasConcept C2776231280 @default.
• W3032181493 hasConcept C2778019345 @default.
• W3032181493 hasConcept C2778695046 @default.
• W3032181493 hasConcept C535046627 @default.
• W3032181493 hasConcept C71924100 @default.
• W3032181493 hasConceptScore W3032181493C126322002 @default.
• W3032181493 hasConceptScore W3032181493C141071460 @default.
• W3032181493 hasConceptScore W3032181493C143998085 @default.
• W3032181493 hasConceptScore W3032181493C203092338 @default.
• W3032181493 hasConceptScore W3032181493C2776231280 @default.
• W3032181493 hasConceptScore W3032181493C2778019345 @default.
• W3032181493 hasConceptScore W3032181493C2778695046 @default.
• W3032181493 hasConceptScore W3032181493C535046627 @default.
• W3032181493 hasConceptScore W3032181493C71924100 @default.
• W3032181493 hasFunder F4320321001 @default.
• W3032181493 hasIssue "15_suppl" @default.
• W3032181493 hasLocation W30321814931 @default.
• W3032181493 hasOpenAccess W3032181493 @default.
• W3032181493 hasPrimaryLocation W30321814931 @default.
• W3032181493 hasRelatedWork W10794003 @default.
• W3032181493 hasRelatedWork W11648075 @default.
• W3032181493 hasRelatedWork W14450087 @default.
• W3032181493 hasRelatedWork W17623510 @default.
• W3032181493 hasRelatedWork W18224072 @default.
• W3032181493 hasRelatedWork W2727520 @default.
• W3032181493 hasRelatedWork W6095507 @default.
• W3032181493 hasRelatedWork W7743602 @default.
• W3032181493 hasRelatedWork W7808089 @default.
• W3032181493 hasRelatedWork W9288866 @default.
• W3032181493 hasVolume "38" @default.
• W3032181493 isParatext "false" @default.
• W3032181493 isRetracted "false" @default.
• W3032181493 magId "3032181493" @default.
• W3032181493 workType "article" @default.